Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi, China.
Department of Gastroenterology, Shenzhen Sixth People's Hospital (Nanshan Hospital), Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen 518052, Guangdong, China.
Gene. 2019 Jan 10;681:15-25. doi: 10.1016/j.gene.2018.09.040. Epub 2018 Sep 25.
This study aimed to identifying and validating therapeutic compounds which might have positive effects on patients with gastric cancer (GC) based on weighted gene co-expression network analysis (WGCNA) and connectivity map (CMap).
We performed WGCNA to gain insights into the molecular aspects of GC. Raw microarray datasets (including 132 samples) were downloaded from the Gene Expression Omnibus (GEO) website. We utilized the WGCNA to identify the coexpressed genes (modules) and modular hub genes after non-specific filtering. Furthermore, these differentially expressed genes were submitted to CMap analysis to identify candidate therapeutic compounds for GC. In experimental part, cell growth inhibition was evaluated by Cell Counting Kit-8 (CCK-8) and colony formation assays. Tumor growth was assessed using nude mice with xenografts established in vivo. QRT-PCR and western blot were used for determination of HDAC2 expression level and immunohistochemistry was performed to quantify HDAC2 in gastric tumor samples.
Through WGCNA and CMap analysis, we found two potential therapeutic compounds, the valproic acid (VPA), which is the histone deacetylase (HDAC) inhibitor and lovastatin. HDAC2 was overexpressed in gastric cancer cell lines including AGS, BGC-823, NCI-N87 and MKN28. Dose-dependent inhibition of gastric cancer cells by VPA and lovastatin was verified in vitro. Apoptosis of GC cells was induced after treatment with VPA and lovastatin through suppressing HDAC2 expression. Furthermore, the inhibition of VPA with cisplatin and lovastatin with cisplatin were also dose-dependent and cisplatin exhibited synergistic effects. In the xenografts, similar results were found.
WGCNA was able to identify significant groups of genes associated with cancer prognosis. Moreover, analysis of gene expression signature using CMap is a powerful way to explore potential therapeutics for human diseases. For treating GC, lovastatin may be a potential drug.
本研究旨在通过加权基因共表达网络分析(WGCNA)和连接图谱(CMap),鉴定并验证可能对胃癌(GC)患者有积极影响的治疗化合物。
我们进行 WGCNA 以深入了解 GC 的分子方面。从基因表达综合数据库(GEO)网站下载原始微阵列数据集(包括 132 个样本)。我们利用 WGCNA 进行非特异性过滤后,识别共表达基因(模块)和模块枢纽基因。此外,这些差异表达基因被提交给 CMap 分析,以鉴定 GC 的候选治疗化合物。在实验部分,通过细胞计数试剂盒-8(CCK-8)和集落形成实验评估细胞生长抑制。通过体内建立异种移植的裸鼠评估肿瘤生长。使用 QRT-PCR 和 Western blot 测定 HDAC2 表达水平,并用免疫组化定量胃肿瘤样本中的 HDAC2。
通过 WGCNA 和 CMap 分析,我们发现了两种潜在的治疗化合物,即丙戊酸(VPA),一种组蛋白去乙酰化酶(HDAC)抑制剂和洛伐他汀。HDAC2 在胃癌细胞系 AGS、BGC-823、NCI-N87 和 MKN28 中过表达。体外实验验证了 VPA 和洛伐他汀对胃癌细胞的剂量依赖性抑制作用。VPA 和洛伐他汀通过抑制 HDAC2 表达诱导 GC 细胞凋亡。此外,VPA 与顺铂的抑制以及洛伐他汀与顺铂的抑制也是剂量依赖性的,顺铂表现出协同作用。在异种移植中也发现了类似的结果。
WGCNA 能够识别与癌症预后相关的显著基因群。此外,使用 CMap 分析基因表达谱是探索人类疾病潜在治疗方法的有力方法。对于治疗 GC,洛伐他汀可能是一种潜在的药物。